Group 1 - The core point of the article is that Kangtai Medical announced the approval of several proposals, including the 2025 semi-annual report and its summary, during the 22nd meeting of the fourth board of directors [2] Group 2 - The announcement was made on the evening of August 28 [2] - The meeting involved the review and approval of multiple proposals [2] - The focus of the approved proposal includes the company's financial reporting for the first half of 2025 [2]

Core Viewpoint - Kangtai Medical has recently received the Medical Device Registration Certificate from the Hebei Provincial Drug Administration for its medical endoscope imaging system [2] Company Summary - The product approved is named "Medical Endoscope Imaging System" [2]

Core Viewpoint - Kangtai Medical has recently obtained a medical device registration certificate for its medical endoscope imaging system, indicating a significant advancement in its product offerings and potential market impact [1] Company Summary - The product, named Medical Endoscope Imaging System, model CMS-HD100, has been approved by the Hebei Provincial Drug Administration [1] - The registration certificate is valid until August 14, 2030, which provides a long-term opportunity for the company to market this product [1] Industry Summary - The medical endoscope imaging system is designed for use in surgical rooms within medical institutions, enhancing the capabilities of optical endoscopes by enabling image capture, storage, and transmission to monitors [1]

Company Overview - Kangtai Medical (SZ 300869) announced its second board meeting of the fourth session on August 27, 2025, where it reviewed the proposal for the 2025 semi-annual report and its summary [1] - As of the report, Kangtai Medical's market capitalization is 7.1 billion yuan [1] Revenue Composition - For the year 2024, Kangtai Medical's revenue composition is as follows: 99.22% from the medical device industry and 0.78% from other businesses [1]

Group 1 - The core viewpoint of the article is that 康泰医学 (Kangtai Medical) reported its 2025 semi-annual financial results, showing positive growth in both revenue and net profit [1] Group 2 - The company's operating revenue reached 218 million yuan, representing a year-on-year increase of 2.72% [1] - The net profit attributable to shareholders of the listed company was 16.94 million yuan, reflecting a significant year-on-year growth of 107.39% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 12.45 million yuan [1] - The basic earnings per share were 0.04 yuan [1]

Core Viewpoint - Kangtai Medical has received a medical device registration certificate for the CMS-HD100 endoscopic imaging system from the Hebei Provincial Drug Administration, which will enhance the company's product line and core competitiveness [1] Summary by Categories Product Development - The CMS-HD100 endoscopic imaging system is designed for image acquisition, storage, and transmission during endoscopic diagnosis or treatment in surgical settings [1] Market Impact - The registration of the new product is expected to enrich the company's product offerings, thereby improving its competitive edge in the market [1] - However, the market performance of the product is subject to various influencing factors, leading to uncertainty [1]

证券代码：300869 证券简称：康泰医学 公告编号：2025-061 债券代码：123151 债券简称：康医转债 康泰医学系统（秦皇岛）股份有限公司 关于 2025 年半年度募集资金存放与使用情况的专项报告 项目 序号 金额（元） 募集资金净额 A 688,270,283.02 截至期初累计发生额 项目投入 B1 92,529,583.96 现金管理收益及利息收入扣除 手续费后的净额 B2 55,120,442.80 项目结项永久性补充流动资金 B3 - 本期发生额 项目投入 C1 20,565,629.47 现金管理收益及利息收入扣除 手续费后的净额 C2 2,136,289.47 项目结项永久性补充流动资金 C3 - 截至期末累计发生额 项目投入 D1=B1+C1 113,095,213.43 现金管理收益及利息收入扣除 手续费后的净额 D2=B2+C2 57,256,732.27 项目结项永久性补充流动资金 D3=B3+C3 - 2、2022 年向不特定对象发行可转换公司债券募集资金使用及结余情况 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、募 ...

产品名称：医用内窥镜摄像系统 型号、规格：CMS-HD100 适用范围：本产品在医疗机构的手术室中使用，在内窥镜诊断或治疗中与光学 内窥镜连接，将内窥镜观察人体体腔的视场区域的图像采集、存储并传输至监视器。 证券代码：300869 证券简称：康泰医学 公告编号：2025-064 债券代码：123151 债券简称：康医转债 康泰医学系统（秦皇岛）股份有限公司 关于获得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 康泰医学系统（秦皇岛）股份有限公司（以下简称"公司"）于近日取得了由 河北省药品监督管理局颁发的《中华人民共和国医疗器械注册证》，具体情况如下： 一、医疗器械注册证内容 注册人名称：康泰医学系统（秦皇岛）股份有限公司 二、对公司的影响及风险提示 CMS-HD100 型医用内窥镜摄像系统（高清）医疗器械注册证的取得，有利于丰 富公司产品线，进一步提高公司的核心竞争力，对公司发展具有正面影响。上述产 品后期实际销售情况取决于未来市场的推广效果及市场的实际需求，公司目前尚无 法准确预测上述产品对公司未来营业收入的影响，敬请广大投资者注意 ...

2025 年半年度非经营性资金占用及其他关联资金往来情况汇总表 单位：万元 非经营性资金占用 资金占用方名称 占用方与上市公 司的关联关系 上市公司核算 的会计科目 2025 年期初占 用资金余额 2025 年 1-6 月占用累 计发生金额（不含利 息） 2025 年 1-6 月占用 资金的利息（如有） 2025 年 1-6 月偿 还累计发生金额 2025 年 1-6 月期 末占用资金余额 占用形成 原因 占用性质 控股股东、实际控制人及其附属企业 - - - - - - - - - - 小计 - - - - - - - - - - 前控股股东、实际控制人及其附属企业 - - - - - - - - - - 小计 - - - - - - - - - - 其他关联方及附属企业 - - - - - - - - - - 小计 - - - - - - - - - - 总计 - - - - - - - - - - 其它关联资金往来 资金往来方名称 往来方与上市公 司的关联关系 上市公司核算 的会计科目 2025 年期初往 来资金余额 2025 年 1-6 月往来累 计发生金额（不含利 息） 2025 年 1-6 月往来 ...

证券代码：300869 证券简称：康泰医学 公告编号：2025-062 债券代码：123151 债券简称：康医转债 康泰医学系统（秦皇岛）股份有限公司 关于 2025 年半年度计提资产减值准备的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 康泰医学系统（秦皇岛）股份有限公司（以下简称"公司"）于 2025 年 8 月 27 日召开第四届董事会第二十二次会议，审议通过了《关于 2025 年半年度计提资产减 值准备的议案》。根据《企业会计准则》《深圳证券交易所创业板股票上市规则（2025 年修订）》等相关规定，本着谨慎性原则，对公司合并财务报表范围内截至 2025 年 6 月 30 日各类存货、应收款项等资产进行了减值测试，判断存在可能发生减值的迹 象，确定了需要计提资产减值准备的资产项目。 一、本次计提资产减值准备情况概述 （一）本次计提资产减值准备的原因 为真实、准确、客观地反映公司截至 2025 年 6 月 30 日的资产状况和财务状况， 根据《企业会计准则》及公司会计政策等相关规定，公司对合并报表范围内可能出 现减值迹象的各类资产进行了减值测试，根 ...